Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

7.86
+0.01000.13%
Post-market: 8.000.1400+1.78%19:58 EDT
Volume:166.96K
Turnover:1.32M
Market Cap:180.23M
PE:-3.73
High:8.00
Open:7.76
Low:7.65
Close:7.85
Loading ...

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Inmune Bio (INMB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
11 Feb

Scotiabank Sticks to Its Buy Rating for Inmune Bio (INMB)

TIPRANKS
·
11 Feb

INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe

MT Newswires Live
·
10 Feb

INmune Bio Inc - to Seek Marketing Authorizations in EU and UK for Cordstrom

THOMSON REUTERS
·
10 Feb

INmune Bio Announces Plan to Submit FDA Biologics License Application (Bla) Seeking Approval of Cordstrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (Rdeb)

THOMSON REUTERS
·
10 Feb

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

GlobeNewswire
·
10 Feb

INmune Bio Inc. Expands Inkmune Trial in Prostate Cancer to Veterans

THOMSON REUTERS
·
28 Jan

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

GlobeNewswire
·
28 Jan

INmune Bio initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
28 Jan

INmune Bio treatment of epidermolysis bullosa receives FDA orphan designation

TIPRANKS
·
07 Jan

Institutions along with retail investors who hold considerable shares inINmune Bio, Inc. (NASDAQ:INMB) come under pressure; lose 11% of holdings value

Simply Wall St.
·
17 Dec 2024

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

GlobeNewswire
·
10 Dec 2024

OmniScience and INmune Bio Partner for Alzheimer’s Trial

Exec Edge
·
05 Dec 2024

INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial

MT Newswires Live
·
05 Dec 2024

INmune Bio, OmniScience announce partnership to accelerate Alzheimer’s trial

TIPRANKS
·
04 Dec 2024

BRIEF-OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Reuters
·
04 Dec 2024

Omniscience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial With Vivo, a Novel Genai Clinical Trial Control Tower

THOMSON REUTERS
·
04 Dec 2024

INmune Bio announces enrollment of 208 patients in Phase 2 trial of early AD

TIPRANKS
·
13 Nov 2024

BRIEF-Inmune Bio Inc. Announces Final Enrollment Of 208 Patients In Phase 2 Trial In Early Alzheimer's Disease

Reuters
·
13 Nov 2024

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

THOMSON REUTERS
·
13 Nov 2024